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Abstract
Aversivememories underlie many types of anxiety disorders. One area of research tomore effectively treat anxiety disorders has
therefore been identifying pharmacological targets to affect memory processes. Among these targets, the metabotropic
glutamate 5 receptor (mGlu5) has received attention due to the availability of drugs to utilize its role in learning andmemory. In
this review, we highlight preclinical studies examining the role of mGlu5 at various stages of aversive learning and its inhibition
via extinction in order to gain a better understanding of its therapeutic potential. We suggest that mGlu5 has distinct roles at
different stages of memory that not only makes it a tricky target, but a double-edged sword as a therapeutic. However, the
selective involvement of mGlu5 in different memory stages allows for certain precision that could be harnessed clinically. We
therefore suggest potential applications, limitations, and pitfalls when considering use of mGlu5 modulators as therapeutics. In
addition, we recommend future studies to address important gaps in this literature, such as sex and age factors in light of
anxiety disorders beingmore prevalent in those demographics.
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1. Introduction
Learning and memory are crucial for survival. In particular, aver-
sive learning allows prevention and avoidance of detrimental out-
comes (e.g., injury, predator etc.) [1]. When expressed perva-
sively, however, thememory of an aversive event can lead to symp-
toms such as heightened fear, avoidance, etc. that can interfere
with necessary activities, resulting in anxiety disorders. Anxiety
disorders are highly prevalent and are among the biggest causes of
health burden worldwide [2]. Yet, current therapeutics often face
issues with efficacy and relapse [3–6]. This has led researchers to
seek novel pharmacotherapies to affect aversive memory to treat
anxiety disorders [7–9].
1.1. Aversive learning andmemory
Aversive memory is widely studied in the laboratory through
Pavlovian conditioning paradigm, in which an initially neutral
conditioned stimulus (CS) is paired with an intrinsically aversive
unconditioned stimulus (US). The CS is typically a discrete cue
such as a tone or a light. Additionally, the context in which the US
takes place can serve as a type of CS that can be associatedwith the
US. After such pairings, presentation of the CS by itself can elicit a
range of behaviors related to the US, such as defensive action asso-
ciated with fear (e.g., immobility) [10]. Notably, Pavlovian condi-
tioning is the process whereby the occurrence of either the CS or
the US is not necessarily dependent on the behavior of the animal
[11].
In contrast, instrumental conditioning refers to the learning of
an action-outcome relationship that requires the animal to per-
form a specific behavior for the US to occur [12]. In aversive in-
strumental learning, an animal may move away from its current
location to escape discomfort or pain [13]. Although rarely treated
as such, the Morris water maze is an example of aversive instru-
mental learning [14]. It involves an animal swimming to find a
submerged platform using distal and/or proximal spatial cues to
escape the water. Alternatively, it could involve an animal avoid-
ing a context or even some flavors. For example, in passive or in-
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hibitory avoidance tasks, an animal is conditioned to avoid certain
areas of a maze after being exposed to an aversive stimulus there
(e.g. footshock, cat urine, etc.) [15, 16]. Similarly in conditioned
taste aversion tasks, animals are conditioned to avoid and/or show
disgust to a flavor (usually done through injection of LiCl to cause
toxicosis in the lab [17]. Importantly, Pavlovian conditioning can
be incorporated into instrumental conditioning as powerful medi-
ators of behavior [18]. Specifically, an instrumental response can
be followed by both the CS and the US. Subsequently, CS can initi-
ate the instrumental response by itself [11, 19, 20]. Behaviors aris-
ing from Pavlovian and/or instrumental conditioning are referred
to as conditioned responses (CRs).
Aversive memories can amplify the excessive worry/stress in
anxiety disorders [21]. Consistent with this idea, one treatment
approach that has received significant attention in the last two
decades is exposure therapy, which often forms a part of cognitive
behavior therapy [7, 8, 22–27]. It typically involves repeatedly ex-
posing a patient to the stimulus that elicits fear in the absence of
any danger. Exposure therapy is based on the process of extinc-
tion, which is the decrease in CR following presentations of the
CS without the US. In instrumental learning, the CR can also be
extinguished when the US no longer follows the CR. Furthermore,
repeated presentations of the CS alone without explicit extinction
training of the action-outcome contingency can also significantly
reduce instrumental CR [19, 28] demonstrating the potency of the
CS in influencing action-outcome behaviors.
Extinction is readily observed across species, and due to its
high clinical relevance, extinction is the most commonly utilized
paradigm to study how the expression of an aversive memory can
be reduced [21, 22, 29–31]. The decrease in CR is due to the animal
learning that the CR or the CS no longer predicts the US. The dom-
inant theory is that extinction involves acquisition of CS-no US
and/or CR-noUSmemory that inhibits the original aversivemem-
ory [21, 29], although there is also evidence for erasure of aversive
memory due to extinction [4, 32–34].
Another commonly studied memory process in the context of
anxiety disorders is reconsolidation, for which a previous consol-
idated memory destabilizes and becomes labile through its reac-
tivation/recall [35, 36] Once recalled, the previously consolidated
memory requires reconsolidation in order to stabilize again, fail-
ingwhich, thememorywould not be retained [37, 38]. This recon-
solidation window therefore allows consolidated memories to be
reinforced or altered, making it an attractive target for therapeu-
tics aiming to alter memories. A focus of contemporary research
has been to target receptors involved in acquisition, extinction, or
reconsolidation of aversivememorieswith the aim to either reduce
initial threat learning or facilitate extinction to ultimately promote
adaptive behaviors in people with anxiety disorders.
1.2 Glutamate andmetabotropic glutamate 5 receptors
The widely accepted putative neural mechanism for learning and
memory is synaptic plasticity, which refers to when the strength
of synaptic transmission is either upregulated or downregulated
[39, 40]. Hebb [41, pp. xix, 335-xix, 335] was the first to describe
a process in which synaptic changes are observed when either a
cell excites another cell repeatedly or is consistently involved in
its excitability. This process causes synaptic changes so that the
first cell’s efficiency in activating the second cell is increased. At
present, the most studied form of synaptic plasticity is long-term
potentiation (LTP) that is found in the hippocampus, prefrontal
cortex, and the amygdala [42, 43], neural structures critical for
aversive learning and memory [44–48]. LTP is a long term en-
hancement in synaptic excitability resulting from coincident ac-
tivity of pre- and post-synaptic elements [49] and is a putative
mechanism for learning andmemory [50].
Glutamate plays an important role in LTP [51]. L-glutamate
is the major excitatory neurotransmitter in the central nervous
system. It acts on ionotropic glutamate receptors (iGluRs) and
metabotropic glutamate receptors (mGluRs). iGluRs are ligand
gated channels, namely N-methyl-D-aspartate (NMDA) recep-
tors, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors and kainate receptors [52]. Typically, excita-
tory transmission happens when glutamate is released into the
synapse and acts on AMPA receptors, causing an influx of depolar-
izing ions. This depolarization can then activate NMDA receptors,
which function as coincidence detectors that are critical for LTP as
well as learning [53]. For example, antagonism of NMDA recep-
tors, can block LTP in the hippocampus in vivo [54]. Correspond-
ingly, animals administered with the NMDA antagonists (±)-3-
(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid or MK-801
show impaired acquisition of spatial learning [55, 56].
Modulating NMDA receptors directly can however be tricky
as NMDA antagonist and agonists are highly associated with cell
toxicity [57, 58], while the efficacy of safer partial agonists like
d-cycloserine has not been supported [59]. Overall, this cre-
ates a need for other targets affecting learning and memory.
mGluRs presents a way to modulate NMDA transmission in a
more controlled manner – a fine tuning mechanism of sorts. The
metabotropic glutamate 5 receptor (mGlu5), in particular, has re-
ceived significant attention as a potential therapeutic target. Com-
pared to other mGluRs, mGlu5 is highly expressed in the amyg-
dala [60, 61], a central structure for fear learning and memory.
Furthermore, compared to other mGluRs, mGlu5 is densely ex-
pressed in the cortical brain regions in the first 3 weeks of devel-
opment [60, 62, 63], which highlights its potential involvement
in emotional learning and memory involved in anxiety disorders
which typically starts in childhood/adolescence [64]. mGlu5 is
a seven transmembrane G protein-coupled receptor belonging to
Group I mGluRs predominantly expressed postsynaptically (typi-
cally extrasynaptic). When activated by the neurotransmitter glu-
tamate, they cause a cascade of chemical changes with leads to
an influx of Ca<sup>2+</sup> via the inositol 1,4,5-triphosphate
and diacyl-glycerol pathway, which cause further downstream ef-
fects [65, 66]. Importantly, mGlu5 is co-localized and interacts
with N-methyl-D-aspartate (NMDA) receptors [67]. For example,
low concentrations of NMDA are able to reverse desensitization of
signaling caused by phosphorylation of specific serine/threonine
molecules inmGlu5, whilst highNMDAconcentrations can inhibit
mGlu5 [68]. Further, mGlu5 positive allosteric modulators (PAM)
are also able to potentiate the activation of NMDA receptor activa-
tion and reverse inhibition by the NMDA antagonist D-APV [69].
Such relationship between NMDA receptors and mGlu5 is be-
lieved to affect long-termpotentiation (LTP). For example, Lu et al.
[70] was the first to show that mGlu5 knockout (KO)mutant mice
had reduced LTP in CA1 and DG region of the dorsal hippocampus.
Early phase LTP seems to be dependent on NMDA receptors and
not onmGlu5 [71]. This is further evidencedbyGerstein etal. [118],
who showed that late- but not early-phase LTP is impaired in hip-
pocampal slices of mice lacking Homer1c (a scaffolding protein as-
sociated withmGlu5). We do note that the purpose of the review is
not to compare andcontrastNMDAvsmGlu5 but tounderstand the
role of mGlu5 in regard to behavior. In addition, mGlu5 on its own
has been shown to be necessary for LTP [72]. Notably, mGlu5 sig-
naling has also been shown to be crucial for NMDA-independent
long-term depression (LTD) and depotentiation [73], which are
also synaptic plasticity mechanisms involved in extinction more
than conditioning [74–77]. Therefore, mGlu5 may particularly be
suited to modulating extinction processes that occur in exposure
therapy.
In addition, mGlu5 are densely expressed in structures impor-
tant for learning and memory such as the hippocampus, amyg-
dala, striatum and nucleus accumbens [78, 79]. Considering that
reduction ofmemory expression following extinction involves the
formation of a new inhibitory memory, mGlu5 manipulation to
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reduce or enhance emotional memory is in fact a “double-edged
sword”. That is, attempts to enhance extinction may enhance
conditioningprocesses,whereas disrupting conditioningmay also
disrupt extinction processes. A clear understanding of the role of
mGlu5 signaling in conditioning and extinction is necessary to ex-
ploit mGlu5 as a therapeutic target. In this mini-review, we de-
scribe and assess the role of mGlu5 in the various stages of ac-
quisition and extinction of aversive memories based on extensive
rodent literature, in order to gain a better understanding of how
to target memory processes using mGlu5 modulators as potential
therapy for anxiety disorders.
2. Metabotropic glutamate 5 receptor in acquisi-
tion andmaintenance of aversive memories
2.1 Acquisition
The role ofmGlu5 in learning andmemory has been demonstrated
firstly using the Morris water maze [70]. While this task is not
typically studied in the context of aversive learning, it requires the
animal’s motivation to escape an aversive situation using spatial
memory. Systemic injections ofmGlu5 PAMsCDPPB (10mg/kg) or
ADX47273 (10 mg/kg) once before each day of Morris water maze
trials enhanced the acquisition of learning inmice, as indicated by
fewer number of days to reach criterion [80]. Although all mice
were trained to criterion, drug-free probe trial showed that mice
previously injected with CDPPB or ADX47273 spent more time in
the target quadrant compared to the vehicle group [80], which
highlights that the effects of mGlu5 PAMs on acquisition of learn-
ing is long-lasting andmay indicate strongermemory overall (Ta-
ble 1).
While such study using PAMs suggests that mGlu5 signaling is
sufficient to acquire aversion-motivated spatial memory, whether
mGlu5 signaling is necessary for acquisition of spatial memory is
less clear. Ballard et al. [81] showed that intraperitoneal (i.p.)
injection of mGlu5 negative allosteric modulator (NAM) MPEP
(3, 10 and 30 mg/kg) in rats once before each day of Morris wa-
ter maze trials had no effects on acquisition (Table 2). Car et al.
[82] also showed in rats that MPEP (1 mg/kg) administered in-
travenously once before each day of Morris water maze trials had
no effects compared to vehicle injections on acquisition. This dis-
crepancy between the effects of PAMs vs. NAMs may be related
to limitationswith pharmacological approaches, including how al-
losteric modulators allow continued orthosteric binding of gluta-
mate. On the other hand, mGlu5 KO mice implicate the function
of mGlu5 at a global and chronic level. Indeed, mGlu5 KO mice
are significantly impaired in acquisition ofMorriswatermaze task
compared to wildtype mice [70, 83]. A limitation in interpret-
ing such finding is that germline KO mice may experience devel-
opmental differences/compensation compared to their wildtype
littermates. In addition, while these studies highlight the hip-
pocampus as the likely locus of mGlu5 effects, deletion of mGlu5
is not anatomically specific in germline KO mice. Tan et al.[84]
addressed some of these limitations by knocking down mGlu5 se-
lectively in the dorsal hippocampus (dHPC) during adulthood us-
ingmGlu5 floxedmice. Significant acquisition deficits in theMor-
ris water maze were observed in that study, providing causal ev-
idence for hippocampus mGlu5 involvement in the acquisition of
aversion-motivated spatial learning.
Consistent with findings using Morris water maze, systemic
injection of themGlu5 NAMMPEP (0.3-30mg/kg) before fear con-
ditioning has been shown to dose-dependently block acquisition
of conditioned fear-potentiated startle to a light CS in rats [85].
Similarly, systemic injection of MTEP (3-30 mg/kg), a mGlu5
NAM with ten-fold greater selectivity than MPEP, prior to fear
conditioning also dose-dependently blocked acquisition of condi-
tioned fear to both context and tone CS in mice [86]. MTEP also
impaired acquistion in a passive avoidance task and conditioned
fear potentiated startle [87]. Although Lu et al. [70] showed no
difference in post-shock freezing between mGlu5 KO and wild-
type mice following a single tone-footshock pairing, with mul-
tiple tone-footshock pairings, Xu et al. [88] showed impaired
post-shock freezing in mGlu5 KO mice to both tone and context.
In terms of studies examining positive modulation of mGlu5, the
mGlu5 PAM CDPPB had no effects when administed pre-training
for a single-trial step-down inhibitory avaoidance learning task
and conditioned taste aversion [89]. Taken together, while these
findings generally highlight that mGlu5 is important for the ac-
quistion of aversive learning, more work is needed to understand
the nuances of their effects in different tasks, and the difference
between positive and negative modulation.
2.2 Consolidation and retrieval
While mGlu5 plays a major role in acquisition of aversive learn-
ing, it does not appear to be necessary for the consolidation of
aversive memory. Administration of the mGlu5 agonist CHPG or
NAM MPEP immediately following fear conditioning did not pro-
duce any effects [90]. Similarly, MTEP given post-conditioning
did not affect conditioned fear to context nor tone CS at test [86].
The lack of involvement of mGlu5 in consolidation of contextual
fear memory is surprising given the critical role of mGlu5 in hip-
pocampal LTD [91],whichhas been shown tobe important for con-
solidation of spatialmemory [92]. Morework, especially using the
selectiveNAMMTEP followingMorriswatermaze training, would
be helpful to delineate whethermGlu5 is involved in consolidation
of spatial memory.
Retrieval of Morris water maze memory does not appear to re-
quire mGlu5. Following Morris water maze training, Lu et al. [70]
showed that mGlu5 KOmice were impaired in probe trial suggest-
ing a possible impairment in retrieval of memory. However, Xu et
al. [88] showed no effect of genotype during the probe trial. It is
likely that the impairment seen in Lu et al. [70] is due to the pre-
existing differences in acquisition. Specifically, mGlu5 KO mice
had significantly higher latency to platform at last acquistion trial
in Lu et al. [70] , whereas there were no genotype differences by
the end of acquisition in Xu et al. [88]. Similarly, Tan et al. [84]
noted no effect of dHPC specific mGlu5 knockdown during probe
trial of Morris water maze. One study did report that 30 mg/kg
of MPEP, but not 3 nor 10 mg/kg, given prior to probe trial had
a small but statistically significant reduction in proportional dis-
tance travelled in platform quadrant [81]. In that study, however,
the platform location was cued and visible.
In retrieval of conditioned fear memory, mGlu5 KO mice were
impaired in freezing to the conditioned context but not to the tone
[70, 88]. However, Xu et al. [88] suggested that this was an ef-
fect on acquisition rather than expression of once-memorized fear
response, suggesting no effect on retrieval of memory. It is in-
deed difficult to assess retrieval effects using mGlu5 KO mice fol-
lowing impairments in acquisition–genotype effects could be due
to carry-over from differences at acquisition. Interestingly, 30
mg/kg MPEP, but not 0.3 or 3.0 mg/kg, administered 60 min be-
fore retrieval test reduced expressionof conditioned fearmeasured
by potentiated startle [85]. At this dose, the authors noted that
MPEPmay be having a broadly anxiolytic effect rather than affect-
ing memory retrieval. It remains equivocal whether mGlu5 is in-
volved in retrieval of aversive memories.
3. Metabotropic glutamate 5 receptor in aversive
memory extinction and reconsolidation
Adaptive learning and behavioral flexibility are highly important
in response to an ever-changing environment. Importantly, it has
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Table 1. Studies using positive allosteric modulators (PAM) or agonists of mGlu5 cited in this paper






Ayala et al. 2009 MWM CDPPB Systemic (I.P.) Pre-acquisition Enhanced
Acquisition
Ayala et al. 2009 MWM ADX47273 Systemic (I.P.) Pre-acquisition Enhanced
Acquisition
Fowler et al. 2011 Inhibitory Avoidance CDPPB Systemic (S.C.) Pre-acquisition No effect
Fowler et al. 2011 Conditioned Taste
Aversion
CDPPB Systemic (S.C.) Pre-acquisition No effect
Sethna et al. 2014 Contextual Fear
Conditioning






















Sethna et al. 2014 Contextual Fear
Conditioning


















Xu et al. 2013 Context and Tone
Fear Conditioning
ADX47273 Systemic (I.P.) Pre-extinction No effect
Sethna et al. 2014 Contextual Fear
Conditioning
CDPPB Systemic I.P.) Pre-extinction Enhanced extinction
acquisition
Ganella et al. 2016 Tone Fear
Conditioning
CDPPB Systemic (S.C.) Pre-extinction Enhanced
consolidation of
extinction at P17 but
not P24 or adult
Xu et al. 2013 Contextual Fear
Conditioning
ADX47273 Systemic (I.P.) Multi Session
Pre-extinction
No effect
Xu et al. 2013 Contextual Fear
Conditioning
ADX47273 Systemic (I.P.) Multi Session
Post-extinction
No effect
Xu et al. 2013 Tone Fear
Conditioning












implications on treatment of pervasively expressed memory dis-
orders – the ability to respond differently to cues with established
associations is crucial to the success of treatment. This canbemod-
elled through extinction and reconsolidation.
3.1 Extinction
Similar to conditioning, extinction is largely a new memory
that involves acquisition, consolidation, and retrieval [9], which
strongly suggests that the role ofmGlu5 signaling in acquisition of
conditioning may also apply for acquisition of extinction. Indeed,
Sethna & Wang [93] showed that pre-extinction systemic injec-
tion ofmGlu5 PAMCDPPB facilitated acquisition of extinction, and
further significantly reduced freezing at test the next day. This
suggests either an effect on acquisition of extinction alone, or an
effect on both acquisition and consolidation of extinction that re-
sulted in reduced freezing. In contrast, an i.p. injection of mGlu5
NAMMPEP before extinction did not affect extinction acquisition
but significantly increased freezing at test the next day [94]. This
effect was replicated whenMPEPwas injected into the infralimbic
cortex (IL), a part of the prefrontal cortex that is critical for con-
solidation of extinction [47, 94, 95]. Those results suggest MPEP
effects on extinction consolidation rather than acquisition.
mGlu5 KO mice also showed impairments in between-session
extinction to context and cue [88], suggesting mGlu5’s role in ex-
tinction consolidation. In contrast,mGlu5 PAMADX47273 system-
ically injected prior to either context or tone extinction sessionhad
no effects during extinction or test, though the lack of ADX47273
effects may be due to insufficient dosing, or due to a floor effect
with the vehicle group freezing very low at test [95]. Interest-
ingly, the role of mGlu5 on extinction consolidation may be age-
dependent. CDPPB or MTEP injection before extinction facilitated
or impaired consolidation of extinction, respectively, in postnatal
day 17 (P17) juvenile rats without affecting P24 or adult rats [96].
The authors proposed that theirfindingswere due to rodentmGlu5
having an unusual neurodevelopmental profile compared to other
mGluRs, with a high expression at birth that steadily decreases
from 3rd week into adulthood [78].
3.2 Reconsolidation
A relatively modern approach to “remove” aversivememories has
been to target reconsolidation [97–101]. This works on the basis
that memories become labile following reactivation – referred to
as a reconsolidation window [37]. Therefore, the short reconsol-
idation period following reactivation may be vulnerable to thera-
peutics to disrupt aversive memory. For example, Monfils et al.
[99] showed that extinction 10 min or 1 hr following fear mem-
ory reactivation (by a single CSpresentation) significantly reduced
spontaneous recovery of fear compared to extinction that was not
followed bymemory reactivation.
Xu et al. [95] aimed to test whether mGlu5 signaling plays a
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Table 2. Studies using negative allosteric modulators (NAM) of mGlu5 cited in this paper






Schulz et al. 2001 Fear Conditioning MPEP Systemic (I.P.) Pre-acquisition Impaired acquisition
Ballard et al. 2005 MWM MPEP Systemic (I.P.) Pre-acquisition No difference in
Acquisition nor probe
Gravius et al. 2005 Passive Avoidance
Response
MTEP Systemic (I.P.) Pre-acquisition Impaired acquisition
Gravius et al. 2005 Conditioned Fear
Potentiated Startle
MTEP Systemic (I.P.) Pre-acquisition Impaired acquisition
Car et al. 2007 MWM MPEP Systemic (I.V.) Pre-acquisition No difference in
Acquisition, nor
probe













l Handford et al. 2014 Fear Conditioning MTEP Systemic (I.P.) Post-acquisition No effect





Gravius et al. 2005 Passive Avoidance
Response

























MPEP IL microinfusion Pre-extinction Normal extinction,
impaired recall 24h
later
Ganella et al. 2016 Tone Fear
Conditioning
MPEP Systemic (S.C.) Pre-extinction Impaired
consolidation of
extinction at P17 but
not P24 or adult
role in reconsolidation. Mice first received three tone-footshock
pairings. The next day, mice received a single but prolonged tone
CS trial, to which they showed high levels of freezing indicating
memory reactivation. Within 45 minutes of this reactivation trial,
mice were given either the mGlu5 PAM ADX47273 or vehicle, and
then received CS extinction. ADX47273 showed no effects during
extinction. At test the next day, however, ADX47273 group showed
reduced freezing compared to vehicle group. The authors sug-
gested that increased mGlu5 signaling during the reconsolidation
window disrupted the original memory. However, it appears that
mGlu5 PAM simply facilitated CS extinction because a critical con-
trol group (i.e., extinction without reactivation) was missing. It
may well be the case that PAM facilitated CS extinction even with-
out any reactivation. Hence this finding may not be indicative of
affecting any reconsolidation process. Future studies can utilize
mGlu5 PAMorNAM following reactivationwithout any extinction,
to really determine whether mGlu5 is involved in reconsolidation.
Specifically, if mGlu5 signaling is necessary and/or sufficient for
reconsolidation, then NAM will disrupt CS memory and/or PAM
will enhance CSmemory when given following reactivation.
Overall, mGlu5 appears to have distinct roles in acquisition and
inhibition of aversive memories. While there still are inconsisten-
cies between studies, the overall conclusion, taking into considera-
tions limitations of each study, is thatmGlu5 is both sufficient and
necessary for acquisition but not consolidation of aversive memo-
ries. While mGlu5 does not seem to play a role in retrieval of aver-
sivememories, studies examining this are limited, andmorework
would be necessary to rule out mGlu5’s role in aversive memory
retrieval. Importantly, mGlu5 appears to play a role in acquisition
and consolidation of extinctionmemory, which hasmajor implica-
tions in themodulation ofmGlu5 as a pharmacotherapeutic target
– a topic we will cover in the next section.
4. Metabotropic glutamate 5 receptor as a poten-
tial pharmacotherapy
Learning andmemory clearly involve mGlu5 signaling, highlight-
ing its powerful potential as a target for anxiety disorder therapeu-
tics. Yet its distinct roles at different stages of memory make it
not only a tricky target, but a double-edged sword as a therapeu-
tic. For acquisition of aversive learning, mGlu5 signaling is likely
necessary and sufficient (Table 1, 2). Consolidation of conditioned
fear or Morris water maze learning appears mGlu5 independent.
Retrieval also is unlikely to involve mGlu5 signaling, with studies
attributing any effects to anxiolysis or pre-existing differences in
acquisition. Therapeutically, mGlu5 not being involved in consoli-
dation of fear memory allows for certain precision – there is then
reduced concern of increasing consolidation of a previous stressful
or traumatic event. This, however, alsomeans that mGlu5 antago-
nist are probably not themost useful therapeutics for lowering the
impact of recent traumatic memories.
Extinction ismGlu5-dependent, withmore evidence for its suf-
ficiency/necessity during consolidation than acquisition (Table 1,
2). Together with the fact that mGlu5 is unlikely to affect re-
trieval ofmemory, increasingmGlu5 signaling using PAMsmay be
an exciting psychological adjunct to strengthen exposure therapy.
Whether taken during or post-therapy, it would not unnecessarily
increase the recall of aversive memory, which is a perceived risk
by clinicians during exposure therapies [102]. However, strong
conclusions cannot be drawnwithout assessingmGlu5’s role in ex-
tinction recall. Exposure therapy typically require repeat sessions,
and it would be important to first understand how mGlu5 agents
may affect extinction recall in subsequent sessions. It would also
be a risk in case of new trauma, with the effects ofmGlu5 agonism
showing to enhance aversive memory acquisition.
The use of mGlu5 PAM during retrieval-reconsolidation win-
dow to disrupt the memory process is also an interesting avenue
to explore, however, the study onmGlu5modulation during recon-
solidation is too limited. Furthermore, techniques that manipu-
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late memories during the retrieval-reconsolidation window work
within a narrow window of time [103] and if not handled properly,
could lead to exacerbation of the problem (multiple consolidations
would serve to reinforce rather than extinguish the original mem-
ory [119]). These issues will only increase with the addition of
pharmacotherapeutics like mGlu5 modulators. Overall, better un-
derstanding of mGlu5 modulators on reconsolidation is needed to
ascertain the efficacy of such an intervention.
In summary, mGlu5 is both sufficient and necessary for ac-
quisition but not consolidation of aversive memories. This indi-
cates that giving an antagonist to disrupt the initial aversivemem-
ory would be impractical because consolidation does not require
mGlu5 signaling. mGlu5 does not seem to play a role in retrieval.
mGlu5 appears to play a role in acquisition and consolidation of ex-
tinction memory. Therefore, the potentially most efficacious way
of applyingmGlu5modulator to alter traumaticmemoryprocesses
would be to use an agonist before or after acute or chronic exposure
therapy.
We do also note that while learnt fear is a well-established
model to study processes underlying the treatment of anxiety dis-
orders [9], it by no means fully capture all aspects of anxiety dis-
orders [104]. While beyond the scope of this review, it would be
important to consider other mGlu5 studies that assess state or
trait anxiety (e.g., elevated plus maze) following stress that may
provide additional information relevant towards anxiety disorders
[105–107].
5. Conclusions
Future efforts with development of mGlu5 modulators as a ther-
apeutic of aversive learning/memory-based disorders should aim
to accurately ascertain effects of mGlu5 PAMs and NAMs on dif-
ferent stages of aversive learning. In particular, the relationship
between mGlu5 signaling and extinction retrieval needs more at-
tention. Further complicating the matters, mGlu5 signaling in
extinction retrieval has been thoroughly assessed with preclini-
cal studies modelling substance use disorders, with NAMs (rather
than PAMs) being promoted because they reduce reinstatement
of drug-seeking in rodents [108]. It would be important to deter-
mine whether mGlu5’s role in extinction recall is dissociated be-
tween aversive vs appetitive memories, given the co-morbidity of
anxiety and substance use disorders [109]. Further work examin-
ing sex difference should also be considered. Sex-specific mGlu5
expression is unknown [110], with studies examining mGlu5 ex-
pression in the brain only using female rats [61–63], or not spe-
cific on sex [60]. These studies showed highest mGlu5 expres-
sion in the first 3 weeks of postnatal life. Consistent with this ob-
servation, highest efficacy inmGlu5 positive or negative allosteric
modulation on extinction was observed in P17male rats relative to
older male rats [96], suggesting that the developmental profile of
mGlu5 expression in males may be similar to females. Neverthe-
less, the possibility of differential rate of decline in mGlu5 expres-
sion across maturation in males versus females remains.
Lastly, it is striking that every mGlu5 behavioral study de-
scribed in this review has used males, despite the higher preva-
lence of anxiety disorders in females over males [111, 112]. In
addition, all but one study used adult rodents, when 75% of all
anxiety disorders are diagnosed by adolescence [64]. There is
clear evidence of age-specific sex differences in aversive learning
and memory [113–117]. Given mGlu5’s consistent role in extinc-
tion, we hope future research to highlight potential age- and sex-
specificmechanisms of howmGluR5 signaling impacts extinction
learning and recall, which are cognitive processes critical for treat-
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